Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.94 USD
+0.01 (0.36%)
Updated Aug 6, 2024 03:39 PM ET
After-Market: $3.00 +0.06 (2.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Lisata Therapeutics, Inc. (LSTA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.50 | $15.00 | $14.00 | 394.88% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Lisata Therapeutics, Inc. comes to $14.50. The forecasts range from a low of $14.00 to a high of $15.00. The average price target represents an increase of 394.88% from the last closing price of $2.93.
Analyst Price Targets (2 )
Broker Rating
Lisata Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/14/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/4/2024 | Brookline Capital Markets | Kemp Dolliver | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $14.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -0.75 |